1-dan master of the unyielding fist of Bayesian inference
6181 stories
·
1 follower

Computational Depth

1 Share

I'm posting from Oxford University where I will be spending the "Hilary Term" (through late March) as a visiting fellow at Magdalen College. If you are relatively local, reach out if you'd like to connect.

I plan to get back into research after thirteen years of administration, working primarily with Rahul Santhanam and his group. I haven't had a significant sabbatical or leave since Amsterdam 30 years ago, which is what comes from changing jobs too often.

Today I'd like to talk about a 2006 paper about a topic I first thought about in Amsterdam and will likely play a role in this visit, Computational Depth: Concept and Applications by Luis Antunes, Dieter van Melkebeek, Vinod Variyam and myself. 

In Amsterdam, I was hosted by Paul Vitányi and Harry Buhrman at CWI, and naturally worked on Kolmogorov complexity, the algorithmic study of randomness, as well as various problems in computational complexity.

Very simple string strings don't have much information. Completely random strings have maximal Kolmogorov complexity but not particularly useful either as we can create our own random strings by flipping coins. Is there some way to measure useful information? 

In particular I had this question: If NP reduces to a sparse set then it has polynomial-size circuits. If NP reduces to a random set then it has polynomial-size circuits. Is this just coincidence or is there a broader principle here?

Charlie Bennett developed a notion of logical depth that has a similar philosophy but it is a difficult definition to work with. Luis Antunes, a student from Porto, came to work with me at NEC Research in New Jersey when I was there around the turn of the century. We developed this simpler notion of computational depth as the difference of two Kolmogorov measures, like time-bounded Kolmogorov complexity minus traditional Kolmogorov complexity. This would be small for both very easy strings and full random strings. With then NEC postdoc (and now Nebraska professor) Vinod Variyam, we found a connection to finding SAT witnesses and with DIMACS and IAS postdoc Dieter van Melkebeek (now Wisconsin professor), we came up with the notion of shallow sets, that generalized both random and sparse sets and, as hoped, if NP reduces to a shallow set than it has polynomial-sized circuits. Luis would title his PhD thesis "Useless Information".

Luis and I would later find a nice connection of computational depth to average-case complexity. 

Computational Depth had a resurgence of popularity with the rise of meta-complexity, with 50 of the original paper's 90 citations coming since 2020.

So I hope to find new applications of computational depth working with Rahul who's at the center of meta-complexity. Maybe computational complexity can help us understand machine learning better based on my frozen concentrate analogy, where the learning process removes the randomness, leaving structured information behind. 

Read the whole story
clumma
3 hours ago
reply
Berkeley, CA
Share this story
Delete

[R] DeepSeek-R1’s paper was updated 2 days ago, expanding from 22 pages to 86 pages and adding a substantial amount of detail.

1 Share
[R] DeepSeek-R1’s paper was updated 2 days ago, expanding from 22 pages to 86 pages and adding a substantial amount of detail.

arXiv:2501.12948 [cs.CL]: https://arxiv.org/abs/2501.12948

submitted by /u/Nunki08 to r/MachineLearning
[link] [comments]
Read the whole story
clumma
3 days ago
reply
Berkeley, CA
Share this story
Delete

The biggest breakthroughs in longevity science in 2025

1 Share
The biggest breakthroughs in longevity science in 2025

At The Longevity Initiative, we’re welcoming the new year with five articles reviewing the old one. From billion-dollar bets on cellular reprogramming to mice living longer, Netflix documentaries and even a leaked hot-mic of Xi and Putin discussing living to 150, 2025 kept aging science in the headlines. The field saw progress, setbacks, and growing debates about policy, equity, and hype.

We’ll be releasing these over the course of this week, starting with 2025 in longevity science (the link in this post). This will be followed by 2025 in longevity business, funding, medicine, and comms, policy and politics on Friday.

I’ll update this post with links as the new pieces go live, or you can follow us on social media (X, LinkedIn, Instagram, Bluesky and Facebook) or sign up for our newsletter to hear about them too.

submitted by /u/statto to r/longevity
[link] [comments]
Read the whole story
clumma
3 days ago
reply
Berkeley, CA
Share this story
Delete

[D] Clean, self-contained PyTorch re-implementations of 50+ ML papers (GANs, diffusion, meta-learning, 3D)

1 Share

This repository collects clean, self-contained PyTorch reference implementations of over 50 machine learning papers, spanning GANs, VAEs, diffusion models, meta-learning, representation learning, and 3D reconstruction.

The implementations aim to:

  • Stay faithful to the original methods
  • Minimize boilerplate while remaining readable
  • Be easy to run and inspect as standalone files
  • Reproduce key qualitative or quantitative results where feasible

Repository (open-source):
https://github.com/MaximeVandegar/Papers-in-100-Lines-of-Code

Interested in hearing where clean, self-contained implementations are sufficient for understanding and reproducing results, and where additional engineering or scale becomes unavoidable.

submitted by /u/papers-100-lines to r/MachineLearning
[link] [comments]
Read the whole story
clumma
3 days ago
reply
Berkeley, CA
Share this story
Delete

Stackoverflow: Questions asked per month over time.

1 Share
submitted by /u/lelanthran to r/programming
[link] [comments]
Read the whole story
clumma
3 days ago
reply
Berkeley, CA
Share this story
Delete

Biosplice submits first osteoarthritis drug to FDA for consideration

1 Share

https://www.biospace.com/press-releases/biosplice-announces-the-submission-of-its-new-drug-application-nda-to-the-fda-for-lorecivivint-lor-to-treat-knee-osteoarthritis

This is the first to be submitted for FDA approval with disease-modifying potential and, if approved, would be the first ever drug to show improvement in pain and joint space width (ie evidence of regrowing cartilage).

Their first phase 2 study failed but their phase 2b with a smaller patient subset (with pain only in one knee) showed improvement.

submitted by /u/sg3510 to r/longevity
[link] [comments]
Read the whole story
clumma
4 days ago
reply
Berkeley, CA
Share this story
Delete
Next Page of Stories